Brouillet Sophie, Ferrieres-Hoa Alice, Fournier Alice, Martinez Guillaume, Bessonnat Julien, Gueniffey Aurore, Gala Anna, Loup Vanessa, Hamamah Samir
Développement Embryonnaire Précoce Humain et Pluripotence, Univ Montpellier, INSERM 1203; Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, CHU Montpellier, Univ Montpellier;
Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, CHU Montpellier, Univ Montpellier.
J Vis Exp. 2020 Oct 23(164). doi: 10.3791/61777.
Human ovarian tissue cryopreservation (OTC) is increasingly used worldwide to preserve female fertility in prepubertal girls and women at risk of premature ovarian insufficiency (POI) in the context of urgent gonadotoxic treatments or ovarian surgery. Fertility preservation is challenging because there is no consensus regarding patient management, preservation fertility strategies, or even technical laboratory protocols, which implies that each procedure must be adapted to the characteristics of the patient profile and its own risk-benefit ratio. During OTC, mature/immature oocytes can be aspirated directly from large/small antral follicles within ovarian tissue samples and/or be released into culture media from growing follicles during ovarian tissue dissection in prepubertal girls and women. In this manuscript, we present a protocol that combines ovarian tissue freezing with the cryopreservation of mature/immature oocytes retrieved from ovarian tissue samples, improving the reproductive potential of fertility preservation. Appropriate collection, handling, and storage of ovarian tissue and oocytes before, during, and after the cryopreservation will be described. The subsequent use and safety of cryopreserved/thawed ovarian tissue samples and oocytes will also be discussed, as well as the optimal timing for in vitro maturation of immature oocytes. We recommend the systematic use of this protocol in fertility preservation of prepubertal girls and women as it increases the whole reproductive potential of fertility preservation (i.e., oocyte vitrification in addition of OTC) and also improves the safety and use of fertility preservation (i.e., thawing of oocytes versus ovarian graft), maximizing the chance of successful childbirth for the patients at risk of POI.
在全球范围内,人类卵巢组织冷冻保存(OTC)越来越多地用于在紧急性腺毒性治疗或卵巢手术的情况下,保护青春期前女孩和有卵巢早衰(POI)风险的女性的生育能力。生育力保存具有挑战性,因为在患者管理、生育力保存策略甚至实验室技术方案方面尚无共识,这意味着每个程序都必须根据患者情况的特点及其自身的风险效益比进行调整。在OTC过程中,成熟/未成熟卵母细胞可直接从卵巢组织样本中的大/小窦卵泡中吸出,和/或在青春期前女孩和女性的卵巢组织解剖过程中从生长卵泡中释放到培养基中。在本手稿中,我们提出了一种将卵巢组织冷冻与从卵巢组织样本中获取的成熟/未成熟卵母细胞的冷冻保存相结合的方案,提高了生育力保存的生殖潜力。将描述在冷冻保存之前、期间和之后卵巢组织和卵母细胞的适当采集、处理和储存。还将讨论冷冻保存/解冻后的卵巢组织样本和卵母细胞的后续使用和安全性,以及未成熟卵母细胞体外成熟的最佳时机。我们建议在青春期前女孩和女性的生育力保存中系统使用该方案,因为它增加了生育力保存的整体生殖潜力(即除了OTC之外的卵母细胞玻璃化),还提高了生育力保存的安全性和实用性(即卵母细胞解冻与卵巢移植),最大限度地提高了有POI风险患者成功分娩的机会。